

**AVEXA**

Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4004
Website www.avexa.com.au

ASX/Media Release

AVEXA APPOINTS EXPERIENCED DRUG DEVELOPMENT SPECIALIST TO BOARD

22 September 2005

Research and development biotechnology company Avexa Limited (ASX: AVX) today announced that Dr Errol Malta is to join its Board as a Non-Executive Director. He is expected to take up the appointment by 1 November 2005.

Dr Malta is currently a director of Australian biotechnology companies Alchemia Ltd and Promics Pty Ltd. and in addition has been a consultant to a number of biotechnology companies in Australia. Previously he held senior management positions with Cortical Pty Ltd as Chairman, and subsequently CEO. Whilst in the US he was Product Development Team Leader responsible for global drug development and commercialisation of a number of different molecules with leading US biotechnology company Amgen Inc. Following his return from the US, he was appointed Director of Scientific Affairs for Amgen Australia Pty Ltd.

"We are delighted to have someone of Errol's calibre join the Avexa Board," said Dr Hugh Niall, Chairman of Avexa Limited. "His track record in drug development in the US, Europe, Japan, Canada and Australia will assist Avexa to move forward."

"Avexa is at a crucial stage of its growth. Errol's strong commercial acumen and his range of skills across all aspects of the drug development and commercialisation process fit with our objectives."

Dr Malta holds a PhD from the University of Melbourne and is a fellow of the Australian Institute of Company Directors. Prior to his industry experience, Dr Malta was Senior Lecturer and researcher at the Victorian College of Pharmacy where he was supported by NHMRC grants and published over 50 scientific papers.

"Dr Malta has successful experience in investigational new drug submissions to the FDA and other regulatory agencies. He also has enormous experience in Phase I/II programs as well as Phase III and IV trials. This is an invaluable resource for Avexa to tap into," said Dr Niall.

Dr Malta will join Dr Hugh Niall, Ms Helen Cameron and Dr Julian Chick on the Board of Avexa.

For more information:

Dr Hugh Niall, Chairman
Avexa Limited
+61 3 9271 1121

Jane Cotter
Oxygen Financial PR
+61 3 9915 6342

www.avexa.com.au

About Avexa

Avexa Limited is an ASX-listed Melbourne-based biotechnology company with a focus on research and development of anti-infectives. The company is developing drugs for the treatment of infectious diseases which have a significant unmet medical need. Avexa is focused on developing therapies for the treatment of HIV/AIDS and other viral infections, and an antibiotic alternative for antibiotic-resistant bacterial infections. The company recently in-licensed the Phase II stage drug, AVX754, from global specialty pharmaceutical company Shire Pharmaceuticals Group. Avexa is currently undertaking Phase IIb trials on AVX754 with results expected in the first quarter of 2006. Avexa has followed the ASX Code of Best Practice for Biotechnology Companies in preparing this announcement.